COSMO PHARM N news, videos and press releases
For more news please use our advanced search feature.
COSMO PHARM N - More news...
COSMO PHARM N - More news...
- Cosmo confirms full redemption in cash of €175m Convertible Bonds
- Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)
- Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
- Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa
- Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
- Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
- Cosmo presents strong H1 2023 operational and financial results
- Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
- Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia
- Cosmo announces Cortiment® approval in Japan
- Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
- Cosmo Pharmaceuticals announces approval of Winlevi® in Canada
- Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting
- Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings
- Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
- Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
- Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
- Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
- Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia
- Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
- Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis
- GI Genius™ named to FORTUNE 2022 “Change the World” list
- Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
- Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria
- Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
- Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
- Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
- Invitation to Cosmo’s Half-Year 2022 Results Webcast on 28 July 2022
- Cosmo announces acceptance of NDA submission of Cortiment® MMX® in Japan
- Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA
